Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
6.8% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
8
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
2.0% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
12
users have liked this narrative
2
users have commented on this narrative
19
users have followed this narrative
8 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.9% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
15
users have liked this narrative
4
users have commented on this narrative
16
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
47.4% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Altice USA
AN
AnalystConsensusTarget
Consensus Narrative from 15 Analysts
Fiber Upgrades And Bundling Will Unlock Future Broadband Opportunities
Key Takeaways Expansion of fiber network and bundling of broadband, mobile, and value-added services are strengthening customer loyalty and driving revenue growth. Operational efficiencies, digitalization, and capital structure improvements are boosting margins, cash flow, and financial flexibility for future investments.
View narrative
US$2.78
FV
15.9% undervalued
intrinsic discount
-2.19%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
6 days ago
author updated this narrative
Arcus Biosciences
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Phase 3 Trials Will Shape Casdatifan Prospects Despite Regulatory Hurdles
Key Takeaways Arcus Biosciences is focusing on casdatifan's late-stage development, promising significant differentiation and competitive advantage in the RCC market. Strong financial partnerships and a long cash runway ensure sustained R&D investment and potential earnings growth through strategic planning.
View narrative
US$28.36
FV
64.5% undervalued
intrinsic discount
7.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
6 days ago
author updated this narrative
Elme Communities
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Robust Multifamily Trends Will Boost Future Asset Sales
Key Takeaways Strong rental demand, tight supply, and strategic market focus drive high occupancy, robust leasing, and support premium asset valuations in core regions. Operational efficiencies and successful management of policy challenges enhance asset appeal, attract investor interest, and boost distributable proceeds for shareholders.
View narrative
US$18.33
FV
7.9% undervalued
intrinsic discount
0.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Immunocore Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 15 Analysts
Aging Demographics And Late-Stage Trials Will Expand Global Markets
Key Takeaways Expanding therapeutic portfolio and successful market entry reduce reliance on a single product and support a foundation for future revenue growth. Strong pricing power, effective cost management, and increased payer reimbursement position the company for stable margins and operational flexibility.
View narrative
US$62.00
FV
47.8% undervalued
intrinsic discount
15.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
6 days ago
author updated this narrative
SHCO
Soho House & Co
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Global Expansion And Operational Improvements Will Drive Future Performance
Key Takeaways Consistent membership growth and new house openings are expected to drive future revenue increases for Soho House & Co. Operational and strategic enhancements, including ERP systems and premium memberships, aim to boost profitability and improve net margins. Financial misstatements and strategic uncertainty may undermine investor confidence, impact strategic decisions, and pose risks to stable future revenue growth.
View narrative
US$9.00
FV
2.4% undervalued
intrinsic discount
7.62%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
6 days ago
author updated this narrative
AMC Entertainment Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Premium Cinema Experiences And Urban Venues Will Redefine Entertainment
Key Takeaways Premium formats, diversified content, and loyalty programs attract new audiences, boost ticket and concession sales, and drive stable, incremental revenue. Portfolio optimization, debt reduction, and strong cash management strengthen profitability, operational efficiency, and capacity for reinvestment.
View narrative
US$3.32
FV
13.9% undervalued
intrinsic discount
5.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
27
users have followed this narrative
6 days ago
author updated this narrative
Teladoc Health
AN
AnalystConsensusTarget
Consensus Narrative from 20 Analysts
Digital Chronic Care And International Expansion Will Unlock Future Markets
Key Takeaways Expanding digital chronic care programs and international presence positions Teladoc for sustainable revenue and membership growth by reaching more patients and underserved markets. Shifting business models and operational efficiencies, including AI-driven automation and insurance-based care, aim to enhance profitability, scalability, and user engagement.
View narrative
US$9.13
FV
19.6% undervalued
intrinsic discount
1.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
39
users have followed this narrative
6 days ago
author updated this narrative
6855
Ascentage Pharma Group International
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Takeda Deal And Olverembatinib Trials Will Open Global Markets
Key Takeaways Ascentage's strategic alliances and NRDL inclusion are set to enhance market reach, boost accessibility, and drive substantial revenue growth. Successful NASDAQ IPO and promising registrational trials position the company to accelerate pipeline development, enhancing future earnings potential.
View narrative
HK$75.50
FV
16.9% overvalued
intrinsic discount
19.70%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Everest Medicines
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
NRDL Approval And Pipeline Efforts Will Counterbalance Potential Risks
Key Takeaways Dependence on NEFECON's success and market strategies in the IgAN space may not deliver the expected revenue, posing financial risks. Heavy investments in sales and R&D could strain margins if they fail to generate proportional revenue growth, impacting near-term earnings.
View narrative
HK$55.53
FV
26.3% overvalued
intrinsic discount
69.29%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Value any company in seconds
Popular companies